Isoquinoline Amide mGluR4 Allosteric Modulators for Neurological Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a scarcity of compounds that effectively potentiate mGluR4 receptors for treating neurological and psychiatric disorders, inflammatory central nervous system disorders, medulloblastomas, metabolic disorders, and taste-related issues associated with glutamatergic dysfunction, and conventional mGluR4 receptor modulators lack satisfactory aqueous solubility and oral bioavailability.
Innovation Solution
Development of compounds with specific structures that act as allosteric modulators of mGluR4 receptors, potentiating their activity without binding to the orthosteric agonist site, thereby enhancing receptor sensitivity and efficacy in treating associated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional mGluR4 receptor modulators are used, then some receptor modulation activity is achieved, but aqueous solubility and oral bioavailability are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structure parameters of mGluR4 modulators. Specific substitutions at defined positions (R1-R6, X1-X6) with various functional groups (fluorine, chlorine, methyl, methoxy, etc.) alter the molecular properties to improve aqueous solubility and oral bioavailability while preserving receptor modulation activity. This is evident in the detailed structural variations presented in the compound formulas throughout the patent.
Solution Approach 2:
The patent employs composite material principles by creating hybrid molecular structures that combine different functional moieties. The modulators integrate aromatic rings, heterocyclic systems, and various substituent groups into composite molecular architectures that achieve both pharmacological activity and improved physicochemical properties for better solubility and bioavailability.
2Adaptability or versatility
If there were more compounds that effectively potentiate mGluR4 receptors, then treatment options for neurological and psychiatric disorders would improve, but currently such compounds are scarce
Solution Approach 1:
The patent applies segmentation by dividing the development of effective mGluR4 potentiators into systematic structural categories. The compounds are organized around core molecular frameworks with defined substitution patterns, allowing methodical exploration of structure-activity relationships. This segmented approach has generated multiple distinct compounds with potentiation activity, expanding the available treatment options for neurological and psychiatric disorders.
Solution Approach 2:
The patent demonstrates universality by developing a series of compounds that share common structural features and mechanisms of action as mGluR4 potentiators. These universally active compounds can address multiple neurological and psychiatric conditions (schizophrenia, cognitive deficits, anxiety, etc.) through their ability to enhance mGluR4 receptor function, thereby expanding treatment versatility across different disorders.
Data Source
AI summary
Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4) of the following formula:synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.